Contineum Therapeutics (CTNM) grants CEO 445,000 stock options at $14.26

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Contineum Therapeutics, Inc. granted CEO and President Carmine N. Stengone a stock option award on January 30, 2026 under its 2024 Equity Incentive Plan. The grant covers 445,000 stock options with an exercise price of $14.26 per share.

The options relate to Class A common stock and vest in equal monthly installments over 48 months, as long as Mr. Stengone continues in service. The options expire on January 29, 2036, and all 445,000 derivative securities are reported as directly owned following the grant.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Stengone Carmine N.

Role CEO and President

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	445,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 445,000 shares (Direct)

Footnotes (1)

[object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 01/30/2026 - 04:56 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stengone Carmine N.

(Last)

(First)

(Middle)

3565 GENERAL ATOMICS COURT, SUITE 200

(Street)

SAN DIEGO

92121

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Contineum Therapeutics, Inc. [ CTNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CEO and President

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$14.26	01/30/2026		A		445,000		⁽¹⁾	01/29/2036	Class A Common Stock	445,000	$0	445,000	D

Explanation of Responses:

1. Options granted under the Issuer's 2024 Equity Incentive Plan. The options shares vest in equal monthly installments over 48 months, subject to the Reporting Person's continuous service.

	/s/ Peter Slover, Attorney-in-Fact	01/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Contineum Therapeutics (CTNM) report?

Contineum Therapeutics reported a stock option grant to CEO Carmine N. Stengone. He received options on 445,000 shares of Class A common stock at a $14.26 exercise price, vesting monthly over 48 months, with expiration on January 29, 2036, under the 2024 Equity Incentive Plan.

Who received the new stock options at Contineum Therapeutics (CTNM)?

CEO and President Carmine N. Stengone received the stock option grant. The Form 4 shows he was awarded 445,000 options on January 30, 2026, tied to Class A common stock, with monthly vesting over 48 months and a final expiration date of January 29, 2036.

What are the key terms of the CTNM CEO’s stock option grant?

The grant covers 445,000 stock options with a $14.26 exercise price per share. These options vest in equal monthly installments over 48 months, contingent on continuous service, and are scheduled to expire on January 29, 2036, according to the company’s 2024 Equity Incentive Plan.

How do the Contineum Therapeutics (CTNM) CEO options vest?

The options vest in equal monthly installments over 48 months. Vesting is conditioned on Carmine N. Stengone’s continuous service with the company, meaning portions of the 445,000 options become exercisable each month until fully vested, subject to that ongoing service requirement.

What does the Form 4 show about CTNM CEO’s option ownership after the grant?

After the reported transaction, Carmine N. Stengone beneficially owns 445,000 derivative securities in the form of stock options. The filing indicates these options are held as a direct ownership position, reflecting the full size of the grant reported on January 30, 2026.